GenSight Biologics S.A. (ENXTPA: SIGHT)
Health Care · Biotechnology · FR
€0.07
-5.00% today · -45.1% 1Y
GenSight Biologics S.A. (ENXTPA: SIGHT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $19.05M and employs 18 people.
Over the last twelve months the share price has lost 45.1%, trading between 0.07 and 0.24.
Tweenvest scores GenSight Biologics S.A. across four factors: quality 12/100, value 52/100, growth 0/100. Its strongest factor is value.
SIGHT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $19.05M
- Revenue (TTM)
- $-286.76K
- P/E
- —
- EPS
- -0.08
- Dividend yield
- —
- Beta (5Y)
- 0.73
- 52-week high
- €0.24
- 52-week low
- €0.07
- Avg volume (3M)
- —
- Shares outstanding
- 234.52M
- Employees
- 18
- Next earnings
- —
About GenSight Biologics S.A.
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
- ISIN
- FR0013183985
- Founded
- 2012
- Listed since
- Jul 13, 2016
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Elicera Therapeutics AB (publ)OM: ELIC | $19.51M | Skr2.90 | +5.08% |
| Nexsen LimitedASX: NXN | $19.50M | AU$0.14 | +7.69% |
| Resverlogix Corp.TSX: RVX | $19.47M | CA$0.08 | -5.88% |
| Inhibitor Therapeutics, Inc.OTCPK: INTI | $19.10M | $0.11 | +12.14% |
| HST Global, Inc.OTCPK: HSTC | $18.91M | $0.13 | -80.90% |
| Dextech Medical ABXSAT: DEX | $18.89M | Skr— | — |
| General Biologicals CorporationTPEX: 4117 | $18.79M | NT$8.61 | -8.31% |
| Quoin Pharmaceuticals, Ltd.NasdaqCM: QNRX | $18.74M | $3.90 | -13.33% |
Figures last refreshed Oct 18, 2026.